Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO Sells $454,772.86 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 10,282 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,162,175.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Amphastar Pharmaceuticals Stock Down 2.1 %

Amphastar Pharmaceuticals stock opened at $41.57 on Monday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $67.66. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.72 and a current ratio of 2.18. The firm’s 50-day simple moving average is $40.49 and its 200 day simple moving average is $44.36. The stock has a market cap of $2.03 billion, a PE ratio of 14.38, a price-to-earnings-growth ratio of 0.75 and a beta of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, May 8th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.73 by $0.20. The firm had revenue of $171.84 million for the quarter, compared to analysts’ expectations of $171.13 million. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. Research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, May 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $71.00 target price on shares of Amphastar Pharmaceuticals in a research report on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Securities Inc. purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter valued at $34,000. YHB Investment Advisors Inc. bought a new position in Amphastar Pharmaceuticals during the first quarter valued at about $27,000. Quadrant Capital Group LLC grew its position in Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after buying an additional 223 shares during the period. Innealta Capital LLC purchased a new stake in Amphastar Pharmaceuticals during the second quarter worth about $55,000. Finally, Blue Trust Inc. raised its position in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.